Trexquant Investment LP Travere Therapeutics, Inc. Transaction History
Trexquant Investment LP
- $7.59 Billion
- Q3 2024
A detailed history of Trexquant Investment LP transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 356,708 shares of TVTX stock, worth $6.94 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
356,708
Previous 174,488
104.43%
Holding current value
$6.94 Million
Previous $1.43 Million
247.98%
% of portfolio
0.07%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding TVTX
# of Institutions
192Shares Held
83.6MCall Options Held
776KPut Options Held
900K-
Armistice Capital, LLC New York, NY7.65MShares$149 Million1.78% of portfolio
-
Black Rock Inc. New York, NY7.64MShares$149 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.9MShares$134 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD4.68MShares$91.2 Million2.23% of portfolio
-
Woodline Partners LP San Francisco, CA4.34MShares$84.5 Million0.55% of portfolio
About Travere Therapeutics, Inc.
- Ticker TVTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 64,173,600
- Market Cap $1.25B
- Description
- Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...